Pancreatic Neuroendocrine Tumor News and Research

RSS

Breakthrough AI tool PANDA shows promise in early detection of pancreatic cancer using non-contrast CT

A deep learning-based approach to use non-contrast computed tomography (CT) scans for high-accuracy detection and classification of pancreatic lesions.

23 Nov 2023

Novel method provides faster and more precise diagnostics in histopathology

Histology is the study of biological tissues at a microscopic level. Also called microscopic anatomy, histology is widely used to provide diagnosis of cancer and other diseases.

30 Apr 2021

Discovery by NETRF-funded researchers may help predict recurrence of pNETs

ARX and PDX1 levels can be measured using immunohistochemistry, a test that stains tumor tissue and is routine in clinical laboratories.

2 Jul 2019

Ipsen's Somatuline Depot Injection 120 mg receives FDA approval for treatment of GEP-NETs

Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, today announced that Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) was approved by the U.S. Food and Drug Administration for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve progression-free survival (PFS).

19 Dec 2014

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

GEP-NETs stands for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). This is a type of rare cancer that is increasing in incidence and prevalence – more on this later.

22 Oct 2014

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced results today from its Phase I extension study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

5 Jun 2012

Montefiore director to host Twitter chat about neuroendocrine tumors on Feb. 29

On February 29, which is Rare Disease Day, Steven Libutti, MD, Vice Chairman of Surgery and Director of the Montefiore Einstein Center for Cancer Care will host a Twitter chat about the signs and symptoms, diagnosis and treatment of neuroendocrine tumors, or NETs, a rare form of cancer.

27 Feb 2012

Niiki Pharma announces positive data from ongoing trial of novel anti-cancer agent NKP-1339

Niiki Pharma Inc. announced interim results from the ongoing Phase I clinical trial of its lead product, NKP-1339. NKP-1339 is a first-in-class transferrin targeted small molecule that down-regulates GRP78, a key regulator of mis-folded protein processing and a tumor survival factor.

20 Sep 2011

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed its Phase I study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

1 Aug 2011

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Threshold Pharmaceuticals, Inc., today announced the initiation of a Phase 1/2 dose escalation clinical trial of TH-302 in combination with sunitinib in patients with advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumor (PNET).

29 Jun 2011

Scientists receive CFCF-AACR grants for carcinoid, pancreatic neuroendocrine tumor research

The American Association for Cancer Research is pleased to announce the recipients of the 2011 Caring for Carcinoid Foundation-AACR Grants for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research and the 2011 Raymond and Beverly Sackler AACR Fellowships for Ileal Carcinoid Tumor Research.

28 Mar 2011

Pancreatic Neuroendocrine Tumor News and Research

Breakthrough AI tool PANDA shows promise in early detection of pancreatic cancer using non-contrast CT

Novel method provides faster and more precise diagnostics in histopathology

Discovery by NETRF-funded researchers may help predict recurrence of pNETs

Ipsen's Somatuline Depot Injection 120 mg receives FDA approval for treatment of GEP-NETs

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Montefiore director to host Twitter chat about neuroendocrine tumors on Feb. 29

Niiki Pharma announces positive data from ongoing trial of novel anti-cancer agent NKP-1339

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Scientists receive CFCF-AACR grants for carcinoid, pancreatic neuroendocrine tumor research

Researchers discover several key mutations in pancreatic neuroendocrine tumors

AACR invites application for carcinoid and pancreatic neuroendocrine tumor research grant

Pfizer reports final results from randomized Phase 3 trial of Sutent

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News